| Nivolumab studied in …STUDIED_INderived10 of 1,426show all (up to 200) |
|---|
| → studied in | NCT05112601Phase 2 · recruiting Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma · 1,426 trials list this drug (493 active) | — | — | Endometrioid Adenocarcinoma,Endometrial Adenocarcinoma,Endometrial Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07392892Phase 2/Phase 3 · recruiting Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer · 1,426 trials list this drug (493 active) | — | — | Malignant Gastric Neoplasm,Esophageal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04123379Phase 2 · active not recruiting Neoadjuvant Nivolumab With CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC) · 1,426 trials list this drug (493 active) | — | — | Hepatocellular Carcinoma,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05136196Phase 2 · recruiting BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study · 1,426 trials list this drug (493 active) | — | — | Melanoma,Malignant Lip and Oral Cavity Neoplasm,Head and Neck Squamous Cell Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05715216Phase 2 · active not recruiting EON: A Single-arm Phase II Study of Etigilimab (OMP-313M32) in Combination With Checkpoint Inhibition (Nivolumab) in Patients With Platinum-resistant, Recurrent Epithelial Ovarian Cancer · 1,426 trials list this drug (493 active) | — | — | Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06203600Phase 2/Phase 3 · recruiting Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial · 1,426 trials list this drug (493 active) | — | — | Esophageal Adenocarcinoma,Gastric Adenocarcinoma,Gastroesophageal Junction Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07401875Phase 1 · recruiting A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK) · 1,426 trials list this drug (493 active) | — | — | Malignant Kidney Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07476326Phase 1 · recruiting Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma · 1,426 trials list this drug (493 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02940301Phase 2 · active not recruiting Ibrutinib and Nivolumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma · 1,426 trials list this drug (493 active) | — | — | Classic Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03866382Phase 2 · recruiting Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors · 1,426 trials list this drug (493 active) | — | — | Malignant Genitourinary System Neoplasm,Large Cell Neuroendocrine Carcinoma,Sarcomatoid Renal Cell Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |